Quantcast
Last updated on April 18, 2014 at 7:29 EDT

Latest acute leukemia Stories

2013-12-09 14:01:57

Findings from nationwide study led by Children's Mercy researcher highlighted at American Society of Hematology Meeting The addition of a monoclonal antibody called gemtuzumab combined with standard chemotherapy has been shown to significantly reduce the risk of relapse and increase rates of disease-free survival in pediatric patients with acute myeloid leukemia (AML). Post-treatment relapse rates are a major indicator of potential for long-term survival in children with the disease....

Genetically Modified Cells Produce Long-term Remissions
2013-12-09 06:46:50

University of Pennsylvania School of Medicine Three and a half years after beginning a clinical trial which demonstrated the first successful and sustained use of genetically engineered T cells to fight leukemia, a research team from the Perelman School of Medicine at the University of Pennsylvania and the Children's Hospital of Philadelphia will today announce the latest results of studies involving both adults and children with advanced blood cancers that have failed to respond to...

2013-12-07 08:20:41

Researchers Unveil First Results in Adult ALL Patients: All Five Patients Had Complete Response to Therapy NEW ORLEANS, Dec. 7, 2013 /PRNewswire/ -- Three and a half years after beginning a clinical trial which demonstrated the first successful and sustained use of genetically engineered T cells to fight leukemia, a research team from the Perelman School of Medicine at the University of Pennsylvania and the Children's Hospital of Philadelphia will today announce the latest results of studies...

2013-12-05 12:29:45

WHITE PLAINS, N.Y., Dec. 5, 2013 /PRNewswire/ -- Many researchers funded by The Leukemia & Lymphoma Society (LLS) will be among those presenting exciting new directions in blood cancer research at the 55th American Society of Hematology (ASH) Annual Meeting and Exposition in New Orleans in early December. The meeting takes place from December 7-10 at the Ernest N. Morial Convention Center. Advances in immune-stimulating therapies, moleculary-targeted drug therapies, including...

2013-12-05 08:30:13

Live Webcast from New York on Wednesday, December 11th SAN DIEGO, Dec. 5, 2013 /PRNewswire/ -- MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, will host an Analyst and Investor Day on Thursday, December 11, 2013 from 12:00 noon to 2:00 p.m. Eastern time in New York City. The event will feature updates by Daniel P. Gold, Ph.D., President and Chief Executive Officer, and Robert D. Mass, MD, Chief Medical Officer,...

2013-12-05 04:20:55

AMSTERDAM, December 5, 2013 /PRNewswire/ -- ~ Prior to the American Society of Hematology Annual Meeting ~ Kiadis Pharma B.V., a clinical stage biopharmaceutical company developing treatments for blood cancers, today announces that its lead product inventor, Denis-Claude Roy, MD, Professor of Medicine at the University of Montreal, is providing the following presentation: "Donor lymphocytes selectively photodepleted of alloreactive T cells can fight...

2013-12-03 16:25:12

Company to Hold Conference Call and Webcast at 9:00 am ET, Wednesday, December 4, 2013 SAN DIEGO, Dec. 3, 2013 /PRNewswire/ -- Ambit Biosciences (Nasdaq: AMBI), a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced a regulatory update after receiving feedback from the U.S. Food and Drug Administration (FDA) on the development of quizartinib (AC220), the Company's lead...

2013-11-26 08:28:07

Live Webcast from New Orleans on Thursday, December 5th SAN DIEGO, Nov. 26, 2013 /PRNewswire/ -- MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, will host its Annual Meeting of Stockholders at 10:00 a.m. Central time on Thursday, December 5, 2013 at the W New Orleans, 333 Poydras Street, New Orleans, LA 70130, to consider and vote on certain matters, including the election of three directors, the ratification of...

2013-11-25 14:40:21

2 separate studies yield key findings for the prevention, diagnosis, treatment and cure for the disease Acute myeloid leukemia (AML) is a group of heterogeneous diseases with considerable diversity in terms of genetic abnormalities. Mutations of CEBPA, a tumour suppressor, are found in about 10 per cent of human AML patients. In two separate studies on CEBPA mutations in AML subtypes, researchers successfully identified and validated a gene known as Sox4 as a potential therapeutic target...

2013-11-19 23:04:55

Reportbuyer.com just published a new market research report: OpportunityAnalyzer: Acute Myeloid Leukemia (AML) - Opportunity Analysis and Forecasts to 2017. London (PRWEB) November 19, 2013 OpportunityAnalyzer: Acute Myeloid Leukemia (AML) - Opportunity Analysis and Forecasts to 2017 Summary Acute myeloid (myelogenous, myelocytic) leukemia is a rapidly progressing blood cancer with a poor overall prognosis. AML is relatively rare, and predominantly affects older adults. AML is a...